ulementary inormation - static-content.springer.com10.1038/ncb3192... · of the introduced stop...
TRANSCRIPT
S U P P L E M E N TA RY I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 1
DOI: 10.1038/ncb3192
Beclin1
VPS34
UVRAG
ATG14
Rubicon
p22 PHOX
p-p40PHOX
ATG7
UNC93B
LC3-II
0 10 20 30 40 50 600
20
40
60
80
100
Time (minutes)
% L
C3+
phag
osom
es
Inert BeadZymosan
0’ 8’ 16’
24’ 32’ 40’
Supplementary Figure 1: LAP is a pathway distinct from canonical autophagy.
GFP-LC3 Zymosan
b
c
10 µm
LC3
Inert Pam3csk4-
bead a
10 µm
Pre-Digitonin Post-Digitonin
LC3-I LC3-II
d
**
15
67
60
90
100
130
65
22
78
40
17
15
Inert Bead
Pam3csk4-Bead
0
20
40
60
80
%L
C3+
ph
ago
som
es
**
Supplementary Figure 1 LAP is a pathway distinct from canonical autophagy. (a) RAW cells were fed inert beads or Pam3csk4-beads for 1 hour. Immunofluorescent staining was performed for LC3B and analyzed by microscopy. Representative images are shown (above), and percent of LC3+ phagosomes is calculated (below). Data are presented as mean ± SD (n=50 cells per genotype pooled from two independent experiments, **p,0.001 using Student’s t test). (b) RAW cells were allowed to phagocytose inert beads or Pam3csk4-beads for 1 hr. Phagosomes were purified using sucrose gradient as described in experimental procedures. Phagosome proteins were solubilized in SDS-PAGE and blotted with the indicated antibodies. The results presented are representative of three independent experiments. (c) RAW-GFP-LC3 cells
were fed inert beads or Alexa Fluor 594-zymosan, and internalization and GFP-LC3 translocation were followed at 4-min intervals for 6 h. Representative images from three independent experiments are shown (top). Time (in minutes) is indicated above each panel. Time course of GFP-LC3 translocation to the inert bead- or zymosan-containing phagosome. Data are presented as mean ± SD (n=75 cells per genotype pooled from three independent experiments, **p,0.001 using Student’s t test). (d) RAW-GFP-LC3 cells were fed inert beads or Alexa Fluor 594-zymosan for 1 hour. Whole cell lysates from pre-digitonin treated samples (right), and digitonin-treated samples (left) were solubilized in SDS-PAGE and blotted for LC3B. The results presented are representative of two independent experiments.
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
2 WWW.NATURE.COM/NATURECELLBIOLOGY
Supplementary Figure 2 Generation of the Rubicon-deficient mouse model using the CRISP/Cas9 method. (a) Western blot analysis of organs from Rubicon+/+ and Rubicon-/- mice, aged 8 weeks. Representative images from three independent experiments are shown. (b) Relative mRNA level of Rubicon of organs from Rubicon+/+ and Rubicon-/- mice (aged 8 weeks) was quantified by real-time PCR. Data normalized to actin. Primers were designed to cover a region upstream of the introduced stop codon (N terminus) and downstream of the introduced stop codon (C terminus). Data are presented as mean ± SD (n=3 independent experiments, **p < 0.001 using Student’s t test; in each experiment, technical triplicate samples of 3 mice per genotype were assessed). (c) Expected and observed frequency of offspring from Rubicon+/- x Rubicon+/- crosses of mice. All genotypes were observed at Mendelian ratios. (d-f) FACS analysis of immune cell composition in the spleen (d), lymph node (e), and thymus (f) of Rubicon+/+, Rubicon+/-, and Rubicon-/- mice, aged 12
weeks. Data are presented as mean ± SD (n=3 independent experiments; in each experiment, technical triplicate samples of 100,000 cells each per genotype were assessed). (g) Rubicon+/+ GFP-LC3+ and Rubicon−/− GFP-LC3+ bone marrow-derived macrophages were fed Alexa Fluor 594-zymosan, and the percent of phagocytosis (% Phagocytosis, left) and the extent of phagocytosis (MFI of Phagocytosed Zymosan, right) was quantified by flow cytometry. Data are presented as mean ± SD (n=3 independent experiments; in each experiment, technical triplicate samples of 50,000 cells each per genotype were assessed). (h) RAW cells were transfected with Scrambled (Scr.) or RAB7 siRNA oligonucleotides. After 48 hours of transfection, cells were fed Pam3csk4-beads for 1 hr. Phagosomes were purified using sucrose gradient as described in experimental procedures. Phagosome proteins were solubilized in SDS-PAGE and blotted with the indicated antibodies. Representative images from two independent experiments are shown.
SpleenLiver
LungBrai
n
SpleenLiver
LungBrai
n0.00.20.40.60.81.01.2
Rela
tive
mRN
A le
vel
0
10
20
30
40
50
60
% o
f spl
een
0
10
20
30
40
50
60
70
80
90
% o
f thy
mus
0
10
20
30
40
50
% o
f lym
ph n
ode
Rubicon+/- x Rubicon+/-
Expected Observed Rubicon+/+ 50 (25%) 58 (29%) Rubicon+/- 100 (50%) 99 (49.5%) Rubicon-/- 50 (25%) 43 (21.5%) Total 200 200
Supplementary Figure 2: Generation of the Rubicon-deficient mouse model using the CRISPR/Cas9 method.
Rubicon+/+Rubicon+/-Rubicon-/-d
a b
e f
c
Rubicon+/+ Rubicon+/+Rubicon-/-Rubicon-/-
N terminus C terminus
B220+ CD3+ CD4+
CD3+ CD8+
NK1.1+ B220+ CD3+ CD4+
CD3+ CD8+
NK1.1+ DN CD4+ SP
CD8+ SP
DP
Rubicon+/+
Rubicon+/-
Rubicon-/-
**
0
20
40
60
80
100
% P
hago
cyto
sis
0
500
1000
1500
2000
MFI
of P
hago
cyto
sed
Zym
osan
+/+ -/- +/+ -/-
Rubicon+/+ Rubicon+/+Rubicon-/-Rubicon-/-
Rubicon
h g
130
43
RAB7
Rubicon
UNC93B
Scr. siRNA
+Pam3csk4-bead RAB7 siRNA
67
23
130
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 3
Beclin1
VPS34
UVRAG
Rubicon
UNC93B
LC3-II
Cre- FIP200f/f
+Pam3csk4-bead Cre+
FIP200f/f
Beclin1
VPS34
UVRAG
Rubicon
UNC93B
LC3-II
ULK1+/+ ULK1-/-
+Pam3csk4 Bead d
NS Rapa. Zymosan
LysM-Cre-
FIP200flox/flox
LysM-Cre+
FIP200flox/flox
10 µm
NS Starvation0
200
400
600
800
MFI o
f GFP
-LC3
Inert Zymosan0
100
200
300
400
MFI o
f GFP
-LC3
LysM-Cre- Beclin1flox/flox
LysM-Cre+ Beclin1flox/floxCre- FIP200f/f
Cre+ FIP200f/f ** a b
NS S I Z
Supplementary Figure 3: LAP occurs independently of the pre-initiation complex.
c
60
90
100
67
130
15
60
90
100
67
130
15
Scrambled siRNA
Ambra1 siRNA
NS Rapa. Zymosan
WIPI2 siRNA
10 µm
NS Starvation0
100
200
300
400
MFI
of G
FP-L
C3
Inert Zymosan0
200
400
600
800
MFI
of G
FP-L
C3Scrambled siRNAAmbra1 siRNAATG18 siRNA
Scrambled siRNA
Ambra1 siRNA
WIPI2 siRNA
** *
e f
NS S I Z
Ambra1
Actin
siRNA
Scr. Ambra1
WIPI2
Actin
siRNA
Scr. WIPI2 g h
43
130
43
49
Supplementary Figure 3 LAP occurs independently of the pre-initiation complex. (a-b) Bone marrow-derived macrophages from LysM-Cre- FIP200flox/flox GFP-LC3+ and LysM-Cre+ FIP200flox/flox GFP-LC3+ mice were left untreated (NS) or were cultured with 200 nM rapamycin (Rapa., a), starvation conditions (S, b), Inert beads (I, b), or Alexa Fluor 594-zymosan (Zymosan or Z, a-b). (c) Bone marrow-derived macrophages from LysM-Cre- FIP200flox/flox GFP-LC3+ and LysM-Cre+ FIP200flox/flox GFP-LC3+ mice were allowed to phagocytose latex beads coated with Pam3csk4 for 1 hr. Phagosomes were purified using sucrose gradient as described in experimental procedures. Phagosome proteins were solubilized in SDS-PAGE and blotted with the indicated antibodies. The results presented are representative of three independent experiments. (d) Bone marrow-derived macrophages from ULK1+/+ and ULK1-/- mice were allowed to phagocytose latex beads coated with Pam3csk4 for 1 hr. Phagosomes were purified using sucrose gradient as described in experimental procedures. Phagosome
proteins were solubilized in SDS-PAGE and blotted with the indicated antibodies. The results presented are representative of three independent experiments. (e-h) RAW-GFP-LC3 cells were transfected with Scrambled, Ambra1, or WIPI2 siRNA oligonucleotides. After 48 hours of transfection, cells were left untreated (NS) or were cultured with 200 nM rapamycin (Rapa., e), starvation conditions (S, f), Inert beads (I, f), or Alexa Fluor 594-zymosan (Zymosan or Z, e-f). GFP-LC3 puncta was assessed at 18 h, and translocation of GFP-LC3 to the LAPosome was assessed at 1 h by confocal microscopy (e) and flow cytometry (f). Whole cell lysates were analyzed for deletion efficiency of Ambra1- (g) or WIPI2-siRNA-treated (h) RAW-GFP-LC3 cells. For (a), (c), (d), and (e), representative images from three independent experiments are shown. For (b) and (f), Data are presented as mean ± SD (n=3 independent experiments, *p<0.05, **p < 0.001 using Student’s t test; for each experiment, technical triplicate samples of 50,000 cells each per genotype were assessed by FACS).
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
4 WWW.NATURE.COM/NATURECELLBIOLOGY
Supplementary Figure 4: LAP utilizes a UVRAG-containing Class III PI3K complex.
Beclin1 Actin
Cre: Beclin1flox/flox
− +
LysM-Cre- Beclin1flox/flox
LysM-Cre+ Beclin1flox/floxCre- Beclin1f/f
Cre+ Beclin1f/f
0
200
400
600
800
1000
MFI
of P
hago
cyto
sed
Zym
osan
0
20
40
60
80
100
% P
hago
cyto
sis
Cre: − + − +
a
b 43
60
LysM-Cre- Beclin1flox/flox
LysM-Cre+ Beclin1flox/floxCre- ATG14f/f
Cre+ ATG14f/f
0
20
40
60
80
100
% P
hago
cyto
sis
0
200
400
600
800
1000
1200
1400
MFI
of P
hago
cyto
sed
Zym
osan
Cre: − + − +
ATG14 Actin
Cre: ATG14flox/flox
− + e
f 43
65 UVRAG Actin
siRNA
Scr. UVRAG
LysM-Cre- Beclin1flox/flox
LysM-Cre+ Beclin1flox/floxScr. siRNA
UVRAG siRNA
0
20
40
60
80
100
% P
hago
cyto
sis
siRNA: Scr. UVRAG 0
300
600
900
1200
1500
1800
MF
I of P
ha
go
cy
tos
ed
Z
ym
os
an
Scr. UVRAG
g
h 43
90
LysM-Cre- Beclin1flox/flox
LysM-Cre+ Beclin1flox/floxCre- VPS34f/f
Cre+ VPS34f/f
0
200
400
600
800
1000
1200
MFI
of P
hago
cyto
sed
Zym
osan
0
20
40
60
80
100
% P
hago
cyto
sis
Cre: − + − +
VPS34 Actin
Cre: VPS34flox/flox
− + c
d 43
100
Beclin1 VPS34 UVRAG ATG14
WT
Rub
icon
-/-
NO
X2-
/- W
T
Iner
t B
ead
Pam
3csk
4-be
ad 3000
6000
9000
12000
15000
18000
Distance across bead
Flu
ore
scen
ce
(Beclin
1)
WT (Pam3csk4-Bead)WT (Inert Bead)
Rubicon-/- (Pam3csk4-Bead)NOX2-/- (Pam3csk4-Bead)
10000
20000
30000
40000
50000
Distance across bead
Flu
ore
scen
ce
(UV
RA
G)
10000
20000
30000
40000
Distance across bead
Flu
ore
scen
ce
(VP
S34) WT (Inert bead)
WT (Pamscsk4-bead) Rubicon-/- (Pam3csk4-bead) NOX2-/- (Pam3csk4-bead)
10 µm
Fluo
resc
ence
(Bec
lin1)
Fluo
resc
ence
(UV
RA
G)
Fluo
resc
ence
(VP
S34
)
i j ATG14
Supplementary Figure 4 LAP utilizes a UVRAG-containing Class III PI3K Complex. (a-b) Whole cell lysates were analyzed for deletion efficiency of LysM-Cre- Beclin1flox/flox and LysM-Cre+ Beclin1flox/flox macrophages (a). Macrophages were fed Alexa Fluor 594-zymosan, and the percent of phagocytosis (% Phagocytosis, left) and the extent of phagocytosis (MFI of Phagocytosed Zymosan, right) were quantified by flow cytometry (b). (c-d) Whole cell lysates were analyzed for deletion efficiency of LysM-Cre- VPS34flox/flox and LysM-Cre+ VPS34flox/flox macrophages (c). Macrophages were fed Alexa Fluor 594-zymosan, and the percent of phagocytosis (% Phagocytosis, left) and the extent of phagocytosis (MFI of Phagocytosed Zymosan, right) were quantified by flow cytometry (d). (e-f) Whole cell lysates were analyzed for deletion efficiency of LysM-Cre- ATG14flox/flox and LysM-Cre+ ATG14flox/flox macrophages (e). Macrophages were fed Alexa Fluor 594-zymosan, and the percent of phagocytosis (% Phagocytosis, left) and the extent of phagocytosis (MFI of Phagocytosed Zymosan, right) were
quantified by flow cytometry (f). (g-h) Whole cell lysates were analyzed for deletion efficiency of Scrambled siRNA- and UVRAG siRNA-treated RAW-GFP-LC3 cells (g). Macrophages were fed Alexa Fluor 594-zymosan, and the percent of phagocytosis (% Phagocytosis, left) and the extent of phagocytosis (MFI of Phagocytosed Zymosan, right) were quantified by flow cytometry (h). (i-j) Bone marrow-derived macrophages from wild-type, Rubicon-/-, or NOX2-/- mice were fed inert beads or Pam3csk4-beads for 1 hour. Immunofluorescent staining was performed for the proteins indicated above each panel and analyzed by microscopy. Representative images (i) and signal intensity profiles (j) for Beclin1, UVRAG, and VPS34 across phagocytosed beads are quantified. Data (intensity measurements across beads) are presented as mean ± SD (n=50 cells per genotype per stain pooled from two independent experiments). For (b), (d), (f) and (h), data are presented as mean ± SD (n=3 independent experiments; technical triplicate samples of 50,000 cells each per genotype per experiment were assessed).
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 5
Supplementary Figure 5: NOX2 is downstream of the Class III PI3K complex and required for LAP
0
20
40
60
80
100
% P
hago
cyto
sis
0
500
1000
1500
MFI
of P
hago
cyto
sed
Zym
osan
NOX2+/+ Rubicon+/+Rubicon-/-NOX2-/- a
+/+ -/- +/+ -/-
NOX2 NOX2
DHE
Cre+ FIP200f/f Cre- FIP200f/f
Cre+ Beclin1f/f Cre- Beclin1f/f
Cre+ VPS34f/f Cre- VPS34f/f
Rubicon-/- Rubicon+/+
NOX2-/- NOX2+/+
Cre+ ATG7f/f Cre- ATG7f/f
Nor
mal
ized
to
Mod
e N
orm
aliz
ed
to M
ode
b
DHE c
0
50
100
150
200
PI(3
)P p
M
+/+ -/-
NOX2
NOX2+/+ Rubicon+/+Rubicon-/-NOX2-/-
c d
67
40
Supplementary Figure 5 NOX2 is downstream of the Class III PI3K Complex and required for LAP. (a) NOX2+/+ GFP-LC3+ and NOX2−/− GFP-LC3+ bone marrow-derived macrophages were fed Alexa Fluor 594-zymosan, and the percent of phagocytosis (% Phagocytosis, left) and the extent of phagocytosis (MFI of Phagocytosed Zymosan, right) were quantified by flow cytometry. (b) Bone marrow-derived macrophages from genetic knockout strains were fed inert beads or Alexa Fluor 594-zymosan and analyzed for ROS production at 1 h by flow cytometry using dihydroethidium (DHE). Filled grey histogram represents inert bead. Representative plots from three independent experiments are shown. (c) NOX2+/+ and NOX2−/− bone marrow-derived macrophages were fed Pam3csk4-beads (30 minutes). mVPS34
was immunoprecipitated from the purified LAPosomes and used in the Class III PI3K Activity assay. Data are presented as pM of PI(3)P,. (d) Bone marrow-derived macrophages from WT, LysM-Cre+ Beclin1flox/flox, and ULK1-
/- mice were allowed to phagocytose latex beads coated with Pam3csk4 for 1 hr. Phagosomes were purified using sucrose gradient as described in experimental procedures. Phagosome proteins were solubilized in SDS-PAGE and blotted with the indicated antibodies. The results presented are representative of three independent experiments. For (a) and (c), data are presented as mean ± SD (n=3 independent experiments; for each experiment, technical triplicate samples of 50,000 cells each per genotype were assessed by FACS).
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
6 WWW.NATURE.COM/NATURECELLBIOLOGY
Supplementary Figure 6: The activity of Rubicon and NOX2 are required for translocation of the downstream conjugation systems to the LAPosome.
WT
Rub
icon
-/-
NO
X2-
/- W
T
Iner
t Bea
d P
am3c
sk4-
bead
Rubicon p22 PHOX p-p40 PHOX ATG7 a
b
10 µm
Supplementary Figure 6 The activity of Rubicon and NOX2 are required for the translocation of downstream conjugation systems to the LAPosome. (a) Bone marrow-derived macrophages from wild-type, Rubicon-/-, or NOX2-/- mice were fed inert beads or Pam3csk4-beads for 1 hour. Immunofluorescent staining was performed for the proteins indicated above each panel and analyzed by microscopy. Representative images from two independent experiments are shown. (b) Model of proposed activity of Rubicon in the crosstalk of Class III PI3K and NOX2 complexes. Recruitment of the Rubicon- and UVRAG-containing Class III PI3K
complex allows for sustained VPS34 activity at the LAPosome, resulting in significant PI(3)P deposition on the LAPosome membrane. This PI(3)P allows for the recruitment of autophagic downstream conjugation systems to the LAPosome and stabilizes the NOX2 complex via its binding to p-p40PHOX. Rubicon itself also stabilizes the NOX2 complex, promoting optimal ROS production. Rubicon mediates the crosstalk between the Class III PI3K and NOX2 complexes, resulting in lipid oxidation and PI(3)P generation, both required for conjugation of LC3 to the lipids of the LAPosome.
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 7
Supplementary Figure 7: PI(3)P and ROS are both required for LAP
0
25
50
75
100
% D
HE
+
Inert BeadZymosanHRP-bead
**
0
10
20
30
40
50
% DH
E+
** Pam3csk4-beadsCatalase-beadsPam3csk4+Catalase-beads
Inert beadInert bead Pam3csk4-bead Catalase-bead Pam3csk4+ Catalase-bead
d e
b
0
20
40
60
80
% D
HE+
Inert beads TBHP
Zymosan Tiron
+ + +
3-MA
- - - -
- - - - - + + + - - - - -
+ + - - - - - - - - -
- - -
**
**
c
I Z H I P C PC
Pam3csk4-bead Tiron 3-MA Inert
+ + + - - - -
- -
- - - - - - - - -
- - +
+ + +
ATG7
LC3-II
UNC93B
15
78
67
0 5 10 15 20 250
20
40
60
80
MF
I (x
1000
) of O
xLD
L
a OxLDL PI(3)P Merge
WT
ULK1-/-
Cre+ Beclin1f/f
NOX2-/- 0 5 10 15 20 250
20
40
60
80
MF
I (x 1
000) o
f P
I(3)P
WTULK1-/-LysM-Cre+ Beclin1flox/flox
NOX2-/-
WT ULK1-/-
Cre+ Beclin1f/f
NOX2-/-
Distance across bead Distance across bead
10 µm
Supplementary Figure 7 PI(3)P and ROS are both required for LAP. (a) Bone marrow-derived macrophages from genetic knockout strains were fed Pam3csk4-beads for 30 minutes. Immunofluorescent staining was performed for oxidized LDL (OxLDL) and PI(3)P and analyzed by confocal microscopy. Representative images (left) and signal intensity profiles for OxLDL (middle) and PI(3)P (left) across phagocytosed beads are quantified. Data (intensity measurements across beads) are presented as mean ± SD (n=60 cells per genotype per stain pooled from two independent experiments). (b) RAW-GFP-LC3 cells were fed inert beads or zymosan, in the presence or absence of tert-butyl hydroperoxide (TBHP, 100 μM, 50 μM), Tiron (1 mM, 0.5 mM), or 3-MA (25 mM, 5 mM). Cells were analyzed for ROS production at 1 h by flow cytometry using dihydroethidium (DHE). (c) RAW-GFP-LC3 cells were fed inert beads or Pam3csk4-beads, in the presence or
absence of Tiron (1 mM, 0.5 mM) or 3-MA (25 mM, 5 mM). After 1 hour of phagocytosis, phagosomes were purified using sucrose gradient as described in experimental procedures. Phagosome proteins were solubilized in SDS-PAGE and blotted with the indicated antibodies. The results presented are representative of four independent experiments. (d) RAW cells were fed inert beads, zymosan, or HRP-coupled beads. Cells were analyzed for ROS production at 1 h by flow cytometry using dihydroethidium (DHE (e) RAW cells were fed inert beads (I), Pam3csk4-beads (P), Catalase-beads (C), or Pam3csk4+Catalase –beads (PC). Cells were analyzed for ROS production at 1 h by flow cytometry using dihydroethidium (DHE). For (b), (d), and (e), data are presented as mean ± SD (n=3 independent experiments, **p < 0.001 using Student’s t test). For each experiment, technical triplicate samples of 50,000 cells each per genotype were assessed by FACS.
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
8 WWW.NATURE.COM/NATURECELLBIOLOGY
Supplementary Figure 8 Clearance of Aspergillus fumigatus requires LAP. (a-b) Bone marrow-derived macrophages from GFP-LC3+ genetic knockout strains were fed inert beads or A. fumigatus-dsRed and analyzed by flow cytometry for GFP-LC3 translocation to the LAPosome (a) and phagocytosis (b). The percent of phagocytosis (% Phagocytosis, left) and the extent of phagocytosis (MFI of Phagocytosed A. fumigatus, right) were quantified by flow cytometry. Data are presented as the average of two independent experiments. (c) Bone marrow-derived macrophages from different genetic knockout strains were fed live A. fumigatus at an MOI of 1, and percentage of killing was calculated as [total
cfu at time-point \ cfu at infection]. (d-e) Mice of different genetic knockout strains (5 mice/strain) were infected intranasally with live A. fumigatus conidia. Percent weight loss was monitored at days 3 and 7 post-infection (d). Serum was collected at day 7 post-infection and analyzed for cytokines via Luminex technology (e). In (c), (d), and (e), data are presented as mean ± SD (n=3 independent experiments, *p<0.05, **p<0.001 using Student’s t test. In (c), technical triplicate samples of each genotype per timepoint per experiment were assessed. In (d) and (e), technical triplicate samples from 5 mice per genotype per timepoint per experiment were assessed.
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 9
Supplementary Figure 9: Western blot scans
Rubicon
ATG7
LC3-II
UNC93B
Beclin1
VPS34
UVRAG
Figure 1e
Rubicon
VPS34
Beclin1
UVRAG
UNC93B
LC3-II
Figure 1f
Supplementary Figure 9 Western blot scans. Phagosome purification samples were prepared as described in Methods. The entire phagosome purification was run on 1 – 2 SDS-PAGE gels due to the relatively lower protein yield compared to whole-cell lysate samples. Membranes were sectioned according to the molecular weight marker, and proteins residing within that range of molecular weights were probed with antibodies listed above. When necessary, membranes were stripped with Restore PLUS
Western Blot Stripping Buffer (Life Technologies), re-blocked in 1X TBST with 5% w/v nonfat dry milk, and probed with fresh antibodies. Images were captured with an Amersham Imager 600 and saved as tiff files. The western images shown are the specific sections that we probed to allow for the analysis of multiple proteins from a limited sample volume. All the original unedited images from key experiments are included in this supplementary figure and are representative of reproducible, independent experiments.
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
10 WWW.NATURE.COM/NATURECELLBIOLOGY
Supplementary Figure 9: Western blot scans
UNC93B
Beclin1
p-p40 PHOX
p22 PHOX
LC3-II
ATG7
Rubicon
Figure 3f
ATG14
LC3-II
UVRAG
UNC93B
Rab5
ATG7
Beclin1
ATG14
Actin
UVRAG
Rab5
ATG7
Figure 2e
ATG12- ATG5
ATG16L
UNC93B
Figure 3g
Supplementary Figure 9 continued
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 11
Figure 6g
LC3-II
UNC93B
ATG7
LC3A
LC3B
GABARAP
UNC93B
GATE16
Figure 5a
Supplementary Figure 9: Western blot scans
UNC93B
p-p40 PHOX
p22 PHOX
Rubicon
UNC93B
LC3-II
Figure 4f Figure 3h
Supplementary Figure 9 continued
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
12 WWW.NATURE.COM/NATURECELLBIOLOGY
Supplementary Figure 9: Western blot scans
Figure S2a
RAB7
Rubicon
UNC93B
Figure S2h
Rubicon
Actin
Beclin1
VPS34
UVRAG
Rubicon
UNC93B
LC3-II
Figure S3c
Supplementary Figure 9 continued
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 13
Supplementary Figure 9: Western blot scans
Beclin1
VPS34
UVRAG
Rubicon
UNC93B
LC3-II
ATG7
LC3-II
UNC93B
Figure S7c
Figure S3d
Supplementary Figure 9 continued
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
14 WWW.NATURE.COM/NATURECELLBIOLOGY
Protein DescriptionLog2
(IgG-bead / Inert-bead)
Log2 (Pam3csk4-bead /
Inert-bead)
Log2 (Avg)
Rubicon Run domain Beclin-1 interacting and cysteine-rich containing protein 1.21 1.35 1.28
Prkcd Protein kinase C δ 1.91 2.63 2.23
Lgals3 Galectin-3 3.21 2.93 3.07
Ifitm3 Interferon-induced transmembrane protein 2 2.36 1.66 2.01
Srrm2 Serine/arginine repetitive matrix protein 2 2.19 1.85 2.02
Myof Myoferlin 3.13 2.68 2.89
02-Sep Septin-2 1.55 1.92 1.995
Ap2s1 AP-2 complex subunit ς 1 2.63 2.25 2.44
Trim33 E3 ubiquitin-protein ligase 2.58 1.69 2.135
Xrcc5 X-ray repair cross-complementing protein 5 1.03 5.98 3.505
Lalba Lactalbumin-α 5.23 1.39 3.31
Saa3 Serum amyloid A-3 3.43 2.54 2.985
Hck Tyrosine-protein kinase HCK 2.28 1.81 2.045
Tmem206 Transmembrane protein 206 1.71 2.44 2.075
Snx20 Sorting nexin-20 2.37 2.83 2.6
Atp8b3 ATPase, class I, type 8B, member 3 0.96 0.81 2
Reps1 RalBP1-associated Eps domain-containing protein 1 4.87 1.29 3.08
Gabarap Gamma-aminobutyric acid receptor-associated protein 2.04 2.33 2.185
Gabarapl1 Gamma-aminobutyric acid receptor-associated protein-like 1 1.17 1.77 1.47
Map1lc3b Microtubule-associated proteins 1A/1B light chain 3B 0.91 0.71 0.81
Pik3c3 Phosphatidylinositol 3-kinase catalytic subunit type 3 1.09 1.17 1.13
Atg3 Ubiquitin-like-conjugating enzyme ATG3 N/A 0.72 0.72
Atg9 Autophagy 9-like 1 protein 0.89 0.53 0.71
Name MM* PAM Chr Start End Strand Location Genestarget 0 NGG chr16 32847302 32847324 - exonic 1700021K19Rik (Rubicon)Off01 2 NGG chrX 156475145 156475167 - intronic Map3k15Off02 3 NGG chr11 16609070 16609092 + intergenic Sec61g,EgfrOff03 3 NGG chr2 30122383 30122405 - exonic Phyhd1Off04 3 NAG chrX 13213424 13213446 - intronic Cask,Gpr34Off05 3 NAG chrX 11686178 11686200 - intronic BcorOff06 3 NAG chr16 7079230 7079252 - intronic Rbfox1Off07 3 NGG chr7 151526315 151526337 - intronic Shank2Off08 3 NGG chr9 49739346 49739368 - intergenic Ncam1, 2310014F07RikOff09 3 NAG chr1 58567252 58567274 + intergenic Orc2, Fam126bOff10 3 NGG chr10 109322284 109322306 + intronic Nav3Off11 3 NAG chr6 91915442 91915464 - intergenic 4930590J08Rik, Fgd5Off12 3 NGG chr19 58049718 58049740 - intronic Atrnl1Off13 3 NAG chr15 83055133 83055155 + intergenic Cyb5r3, A4galtOff14 6 NGG chr11 73029624 73029646 - intronic Shpk Off15 6 NAG chr3 118690448 118690470 + intronic DpydOff16 6 NAG chr5 67173306 67173328 - intronic Limch1Off17 6 NAG chr8 37646560 37646582 - intronic Dlc1Off18 7 NGG chr14 85943851 85943873 + intergenic Pcdh17, Diap3Off19 4 NGG chr4 81475756 81475778 + intergenic Mpdz, NfibOff20 2+ 1bp del NAG chr1 9344457 9344457 - intergenic Sntg1, Rrs1Off21 2+ 1bp ins NAG chr2 26861506 26861506 + intronic Adamts13
*MM, Number of mismatches in the 20mer target sequence; Chr, chromosome; Start and End, begin and end of the coordinates of the sites (NCBI37/mm9 mouse assembly).
Supplementary Table 1 Proteins uniquely associated with the LAPosome. Proteins associated with the LAPosome with a log2 SILAC ratio greater than 0.7 to the inert bead phagosome. The protein name, description, Log2 ratios for both IgG-bead/inert bead and Pam3csk4-bead/inert beads, and the average Log2 ratio are shown.
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 15
Protein DescriptionLog2
(IgG-bead / Inert-bead)
Log2 (Pam3csk4-bead /
Inert-bead)
Log2 (Avg)
Rubicon Run domain Beclin-1 interacting and cysteine-rich containing protein 1.21 1.35 1.28
Prkcd Protein kinase C δ 1.91 2.63 2.23
Lgals3 Galectin-3 3.21 2.93 3.07
Ifitm3 Interferon-induced transmembrane protein 2 2.36 1.66 2.01
Srrm2 Serine/arginine repetitive matrix protein 2 2.19 1.85 2.02
Myof Myoferlin 3.13 2.68 2.89
02-Sep Septin-2 1.55 1.92 1.995
Ap2s1 AP-2 complex subunit ς 1 2.63 2.25 2.44
Trim33 E3 ubiquitin-protein ligase 2.58 1.69 2.135
Xrcc5 X-ray repair cross-complementing protein 5 1.03 5.98 3.505
Lalba Lactalbumin-α 5.23 1.39 3.31
Saa3 Serum amyloid A-3 3.43 2.54 2.985
Hck Tyrosine-protein kinase HCK 2.28 1.81 2.045
Tmem206 Transmembrane protein 206 1.71 2.44 2.075
Snx20 Sorting nexin-20 2.37 2.83 2.6
Atp8b3 ATPase, class I, type 8B, member 3 0.96 0.81 2
Reps1 RalBP1-associated Eps domain-containing protein 1 4.87 1.29 3.08
Gabarap Gamma-aminobutyric acid receptor-associated protein 2.04 2.33 2.185
Gabarapl1 Gamma-aminobutyric acid receptor-associated protein-like 1 1.17 1.77 1.47
Map1lc3b Microtubule-associated proteins 1A/1B light chain 3B 0.91 0.71 0.81
Pik3c3 Phosphatidylinositol 3-kinase catalytic subunit type 3 1.09 1.17 1.13
Atg3 Ubiquitin-like-conjugating enzyme ATG3 N/A 0.72 0.72
Atg9 Autophagy 9-like 1 protein 0.89 0.53 0.71
Name MM* PAM Chr Start End Strand Location Genestarget 0 NGG chr16 32847302 32847324 - exonic 1700021K19Rik (Rubicon)Off01 2 NGG chrX 156475145 156475167 - intronic Map3k15Off02 3 NGG chr11 16609070 16609092 + intergenic Sec61g,EgfrOff03 3 NGG chr2 30122383 30122405 - exonic Phyhd1Off04 3 NAG chrX 13213424 13213446 - intronic Cask,Gpr34Off05 3 NAG chrX 11686178 11686200 - intronic BcorOff06 3 NAG chr16 7079230 7079252 - intronic Rbfox1Off07 3 NGG chr7 151526315 151526337 - intronic Shank2Off08 3 NGG chr9 49739346 49739368 - intergenic Ncam1, 2310014F07RikOff09 3 NAG chr1 58567252 58567274 + intergenic Orc2, Fam126bOff10 3 NGG chr10 109322284 109322306 + intronic Nav3Off11 3 NAG chr6 91915442 91915464 - intergenic 4930590J08Rik, Fgd5Off12 3 NGG chr19 58049718 58049740 - intronic Atrnl1Off13 3 NAG chr15 83055133 83055155 + intergenic Cyb5r3, A4galtOff14 6 NGG chr11 73029624 73029646 - intronic Shpk Off15 6 NAG chr3 118690448 118690470 + intronic DpydOff16 6 NAG chr5 67173306 67173328 - intronic Limch1Off17 6 NAG chr8 37646560 37646582 - intronic Dlc1Off18 7 NGG chr14 85943851 85943873 + intergenic Pcdh17, Diap3Off19 4 NGG chr4 81475756 81475778 + intergenic Mpdz, NfibOff20 2+ 1bp del NAG chr1 9344457 9344457 - intergenic Sntg1, Rrs1Off21 2+ 1bp ins NAG chr2 26861506 26861506 + intronic Adamts13
*MM, Number of mismatches in the 20mer target sequence; Chr, chromosome; Start and End, begin and end of the coordinates of the sites (NCBI37/mm9 mouse assembly).
Supplementary Table 2 Off-target sequences of Rubicon-E5F2 target site
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
16 WWW.NATURE.COM/NATURECELLBIOLOGY
PrimerRubicon-E5F2-F TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGCTCAGATCGATGCATCCARubicon-E5F2-R GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTGGATGCATCGATCTGAGCCT7-Rubicon-E5F2 TTAATACGACTCACTATAGGCTCAGATCGATGCATCCA
gRNA-R AAAAGCACCGACTCGGTGCCRubicon-F1 AGCAGAGGGTTTTATGCGCTRubicon-R1 CCACCACACCCAACTCTTCA
Rubicon-Off01-F2 GTTGCCTCACTCAGGATGGTRubicon-Off01-R2 CTCCTTTCCTGTCAGGCTGGRubicon-Off02-F1 GCTCCCCAGTGACCATGTAGRubicon-Off02-R1 GGATGAAGTATGGGCAGCCTRubicon-Off03-F1 TCCACCCCCTGTATGGTAGGRubicon-Off03-R1 ACTTGAGGGATCAAGCCAGCRubicon-Off04-F1 GGAAGAGGAAGTGGCTGGTGRubicon-Off04-R1 ACCTGGTACACAGAGAGGCARubicon-Off05-F1 GGGTGGCCAACCTTGAACTRubicon-Off05-R1 AAACCTGGTCCCAGGAGCTARubicon-Off06-F1 CCAGGAAGGACTGAGCATGGRubicon-Off06-R1 TCCGAGGCACTTGTAGATGCRubicon-Off07-F1 GGCTGCCTGACTCATGGAATRubicon-Off07-R1 CCAGACCTCCTCTGTCCTGARubicon-Off08-F1 ACTGGGTGCTAAATCAGGGCRubicon-Off08-R1 CTGAGAAAGCTACGACGGGGRubicon-Off09-F1 GGCCTCACCCAAAGGCTATTRubicon-Off09-R1 TCACACCAGCTGAACCAGTCRubicon-Off10-F2 TTCCACCAGCAGCATCTGAGRubicon-Off10-R2 TCTTGATGCCTGCAACCAAACRubicon-Off11-F1 ACCAGCAAGTACTCTTCGGCRubicon-Off11-R1 TGATAGGTTGTGAGGCGCAGRubicon-Off12-F1 TCAGTTGTGACTGGGGTTTAGGRubicon-Off12-R1 ACCTTCCTAGGGTGCTCACARubicon-Off13-F1 CATGAAAGCGGCCAGTGATGRubicon-Off13-R1 CTCAGCACCTGGGGGTAATCRubicon-Off14-F1 ACATGGAGGGTTCTGGGAGTRubicon-Off14-R1 ACCCCTTAGTTCATGCCAGCRubicon-Off15-F1 AAAAGACTTAGAGGCGCCCARubicon-Off15-R1 ACAATGGTAGCTCCGGATGACRubicon-Off16-F1 CTGCCCAGTGTGGGAGTTAGRubicon-Off16-R1 ACCCCAGAGTATCAGGGCATRubicon-Off17-F1 GGGATGCAGCGGATAGTCAARubicon-Off17-R1 CTCATCTGTGCCTGGCTGAARubicon-Off18-F1 TCTTCCTCTTCAGTTGCCTACARubicon-Off18-R1 GCTAAGGGTGCAGTTGTTGCRubicon-Off19-F1 GTCCAACTTTGCAAGGCCAGRubicon-Off19-R1 CCATGCCCCCTTTCCTGATTRubicon-Off20-F1 TAGCCCATCTCCTGCTCACTRubicon-Off20-R1 TGTACTGTGCCACCAGACAGRubicon-Off21-F1 TGTCTTTCATTGGCCCGGAGRubicon-Off21-R1 ACTGGAGTTGTGTGCCAGAG
Sequence
Supplementary Table 3 Sequencing and targeting primers for Rubicon-E2F2 target site
© 2015 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 17
PrimerRubicon-E5F2-F TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGCTCAGATCGATGCATCCARubicon-E5F2-R GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTGGATGCATCGATCTGAGCCT7-Rubicon-E5F2 TTAATACGACTCACTATAGGCTCAGATCGATGCATCCA
gRNA-R AAAAGCACCGACTCGGTGCCRubicon-F1 AGCAGAGGGTTTTATGCGCTRubicon-R1 CCACCACACCCAACTCTTCA
Rubicon-Off01-F2 GTTGCCTCACTCAGGATGGTRubicon-Off01-R2 CTCCTTTCCTGTCAGGCTGGRubicon-Off02-F1 GCTCCCCAGTGACCATGTAGRubicon-Off02-R1 GGATGAAGTATGGGCAGCCTRubicon-Off03-F1 TCCACCCCCTGTATGGTAGGRubicon-Off03-R1 ACTTGAGGGATCAAGCCAGCRubicon-Off04-F1 GGAAGAGGAAGTGGCTGGTGRubicon-Off04-R1 ACCTGGTACACAGAGAGGCARubicon-Off05-F1 GGGTGGCCAACCTTGAACTRubicon-Off05-R1 AAACCTGGTCCCAGGAGCTARubicon-Off06-F1 CCAGGAAGGACTGAGCATGGRubicon-Off06-R1 TCCGAGGCACTTGTAGATGCRubicon-Off07-F1 GGCTGCCTGACTCATGGAATRubicon-Off07-R1 CCAGACCTCCTCTGTCCTGARubicon-Off08-F1 ACTGGGTGCTAAATCAGGGCRubicon-Off08-R1 CTGAGAAAGCTACGACGGGGRubicon-Off09-F1 GGCCTCACCCAAAGGCTATTRubicon-Off09-R1 TCACACCAGCTGAACCAGTCRubicon-Off10-F2 TTCCACCAGCAGCATCTGAGRubicon-Off10-R2 TCTTGATGCCTGCAACCAAACRubicon-Off11-F1 ACCAGCAAGTACTCTTCGGCRubicon-Off11-R1 TGATAGGTTGTGAGGCGCAGRubicon-Off12-F1 TCAGTTGTGACTGGGGTTTAGGRubicon-Off12-R1 ACCTTCCTAGGGTGCTCACARubicon-Off13-F1 CATGAAAGCGGCCAGTGATGRubicon-Off13-R1 CTCAGCACCTGGGGGTAATCRubicon-Off14-F1 ACATGGAGGGTTCTGGGAGTRubicon-Off14-R1 ACCCCTTAGTTCATGCCAGCRubicon-Off15-F1 AAAAGACTTAGAGGCGCCCARubicon-Off15-R1 ACAATGGTAGCTCCGGATGACRubicon-Off16-F1 CTGCCCAGTGTGGGAGTTAGRubicon-Off16-R1 ACCCCAGAGTATCAGGGCATRubicon-Off17-F1 GGGATGCAGCGGATAGTCAARubicon-Off17-R1 CTCATCTGTGCCTGGCTGAARubicon-Off18-F1 TCTTCCTCTTCAGTTGCCTACARubicon-Off18-R1 GCTAAGGGTGCAGTTGTTGCRubicon-Off19-F1 GTCCAACTTTGCAAGGCCAGRubicon-Off19-R1 CCATGCCCCCTTTCCTGATTRubicon-Off20-F1 TAGCCCATCTCCTGCTCACTRubicon-Off20-R1 TGTACTGTGCCACCAGACAGRubicon-Off21-F1 TGTCTTTCATTGGCCCGGAGRubicon-Off21-R1 ACTGGAGTTGTGTGCCAGAG
Sequence
Primer SequenceRubicon N-terminus For. TCAGGGTGTAGTGCATGGTTRubicon N-terminus Rev. GACGCATCCGGACTATAAGGRubicon C-terminus For. GTCAGGCCACAAGCCTATAARubicon C-terminus Rev. AGCAGTAAGGAACCCACTATTC
mIL-1β For. AAGGAGAACCAAGCAACGACAAAAmIL-1β Rev. TGGGGAACTCTGCAGACTCAAACTmIL-6 For. GACAACTTTGGCATTGTGGmIL-6 Rev. ATGCAGGGATGATGTTCTG
mIL-12p40 For. ACAGCACCAGCTTCTTCATCAGmIL-12p40 Rev. TCTTCAAAGGCTTCATCTGCAA
mTNFα For. ATGAACGCTACACACTGCATCmTNFα Rev. CCATCCTTTTGCCAGTTCCTCmActin For. ATGGAGGGGAATACAGCCCmActin Rev. TTCTTTGCAGCTCCTTCGTT
Supplementary Table 4 Real-time PCR primers
© 2015 Macmillan Publishers Limited. All rights reserved